GDRX — GoodRx Holdings, Inc.
Is GDRX overbought or oversold? Here is the current MarketMoodz read.
GoodRx Holdings, Inc. (GDRX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Health Information Services) last closed at $3.51. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$3.51
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryHealth Information Services
See all oversold Healthcare stocks →
AI analysis
GoodRx is a well-known consumer prescription-savings and digital-health platform with multiple monetization levers and a large addressable market. Near-term performance will hinge on sustaining prescription volumes, managing margin conversion from subscription and telehealth initiatives, and executing partnerships while defending against competitive and regulatory headwinds. Given current trading levels, the profile suggests limited near-term upside absent clear evidence of accelerating subscription take-rates or materially improved enterprise traction; downside risks include pricing pressure, volume declines, and potential dilution.
Key factors
- Strong consumer-oriented value proposition: GoodRx is a widely recognized price-comparison and savings platform for prescription drugs, driving steady user engagement and referral volume.
- Diverse revenue mix: combination of prescription savings, subscription services (GoodRx Gold), telehealth, and ad/partnership revenue provides multiple monetization channels.
- Cost structure and margin leverage: ability to scale digital traffic and subscriptions can improve gross margins but recent profitability has been uneven.
- Large addressable market: persistent price sensitivity in U.S. pharma and continued payer/provider interest in cost-management solutions sustain long-term TAM.
- Partnership and distribution opportunities: potential to expand B2B deals with pharmacies, PBMs, and digital-health partners to grow transaction volume and recurring revenue.
- Macroeconomic and market tone supportive of healthcare/consumer-health digital plays in the near term, with earnings-driven risk-on sentiment possibly benefiting short-term trading interest.
Risks
- Revenue volatility from prescription volumes and seasonality: declines in prescription fills or lower-margin channels could compress top-line.
- Competitive pressure from large-cap entrants (retailers, PBMs, insurers) and verticalized telehealth players that could erode pricing power or share.
- Regulatory and policy risk: changes in drug-pricing rules, PBM/insurer arrangements, or enforcement actions could materially affect business model.
- Capital/financing risks and dilution: mid-cap financing activity in the sector and potential need for capital could lead to dilution if liquidity tightens.
- Dependence on consumer behavior and reimbursement: reductions in discretionary health spending or shifts to insurer-negotiated pricing may reduce addressable transactions.
- Limited visibility into large enterprise contracts and long sales cycles for B2B expansion can delay expected revenue growth.
- Data/privacy/security incidents could harm brand and user trust, reducing engagement and conversion.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for GDRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.